Epigenica AB unveils EpiFinder cNUC for multiplexed epigenomic profiling from liquid biopsies
Epigenica AB, a Swedish life sciences technology company, has launched EpiFinder™ cNUC, a kit-based platform designed to simultaneously profile multiple histone posttranslational modifications (PTMs) and DNA methylation directly from circulating nucleosomes in plasma and serum samples.
A new approach to circulating nucleosome analysis
The platform is described as the first product capable of co-profiling up to five histone PTMs alongside DNA methylation in a single workflow. Crucially, it operates directly on circulating nucleosomes without requiring prior nucleosome extraction or DNA purification – a step that has traditionally added cost and complexity to liquid biopsy workflows while risking loss of biological material.
Starting from as little as 200 µL of plasma or serum, EpiFinder cNUC can process up to 24 samples simultaneously. The design eliminates the need for spike-in controls, and the company states the assay generates quantitative, reproducible data with reduced hands-on time and technical variability.
Multiplexing and workflow integration
Underpinning the platform is Epigenica’s patented hmqChIP (high-throughput, multiplex, quantitative ChIP-seq) technology. Users can tailor which epigenetic marks to interrogate and adjust sample throughput to suit project requirements, from early-stage exploratory work through to large-scale biomarker development programmes.
An open-source data analysis pipeline accompanies the kit, requiring no advanced bioinformatics expertise, enabling laboratories to move from raw sequencing output to biological interpretation without specialist computational support.
Intended applications
EpiFinder cNUC is positioned to support translational research and biomarker discovery across oncology, ageing, inflammation, and related therapeutic areas. Stated applications include early disease detection, patient stratification, disease-progression monitoring, and treatment-response evaluation.
“With EpiFinder cNUC, we aim to make epigenomics more accessible, scalable, and actionable for researchers working to understand complex diseases,” said Mohamad Takwa, CEO of Epigenica. “By enabling direct and multiplexed analysis of circulating nucleosomes, this product brings a new level of clarity to liquid biopsy research and supports the scientific community in accelerating discoveries that can ultimately benefit patients.”
EpiFinder cNUC is available as a ready-to-use kit or as a fully supported service offering.
For more information, visit: www.epigenica.se
Digital issue: Please click here for more information
